{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016997","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.111684+00:00","generated_at":"2026-05-21T06:31:15.032906+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxart gets BARDA approval to start dosing 10,000 participants in Phase 2b COVID vaccine trial","bullets":["BARDA approved initiation of dosing in 10,000-participant Phase 2b trial of oral COVID-19 vaccine.","First patient expected to be dosed in Q2 2025, per CEO Steven Lo.","Trial is double-blind, randomized, comparator-controlled vs approved mRNA COVID-19 vaccine.","Funding under Project NextGen via RRPV Consortium valued at up to $460.7M.","Funding from HHS/ASPR/BARDA under Other Transaction 75A50123D00005."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016997","json":"https://secwatch.observer/filing/0001437749-25-016997.json","markdown":"https://secwatch.observer/filing/0001437749-25-016997.md","text":"https://secwatch.observer/filing/0001437749-25-016997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925016997/0001437749-25-016997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925016997/vxrt20250515_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T06:31:15.032906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}